Fig. 2

Kowndown of PSMD7 expression restrains the PC cell proliferative capacity in vitro and in vivo. (A) The mRNA of PSMD7 in AsPC-1 and PANC-1 cells transfected with shPSMD7 or shNC assayed via qRT-PCR. (B) PSMD7 knockdown in AsPC-1 and PANC-1 cells was validated via western blotting. (C) The proliferative abilities of AsPC-1 and PANC-1 PC cells with shNC or shPSMD7 treatment was detected separately via CCK-8. (D) Proliferative capacities of AsPC-1 and PANC-1 cells that were transfected with shPSMD7 or shNC were assayed with EdU, and the scale bar represents 50 μm, **p < 0.01. (E) Evaluation of mice that were injected with luciferase-expressing PANC-1/shPSMD7 or PANC-1/shNC cells via the IVIS imaging system. (F) Tumour volumes of the PANC-1/shPSMD7 and PANC-1/shNC groups. Volumes of tumours are expressed as the mean ± SD, n = 6. (G) Tumour weight of the shPSMD7 and shNC groups. n = 6. (H) The images of tumors the PANC-1/shPSMD7 and PANC-1/shNC groups. (I) and (J) Immunohistochemistry (IHC) analysis of PSMD7 and Ki-67 expression in tumours of the PANC-1/shPSMD7 and PANC-1/shNC groups, scale bar denotes 100 μm. n = 3, *p < 0.05, **p < 0.01